SEARCH

SEARCH BY CITATION

References

  • Accili D., Fishburn C. S., Drago J. et al. (1996) A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc. Natl Acad. Sci. USA 93, 19451949.
  • Banasikowski T. J., Bespalov A., Drescher K., Behl B., Unger L., Haupt A., Schoemaker H., Sullivan J. P., Gross G. and Beninger R. J. (2010) Double dissociation of the effects of haloperidol and the dopamine D3 receptor antagonist ABT-127 on acquisition vs. expression of cocaine-conditioned activity in rats. J. Pharmacol. Exp. Ther. 335, 506515.
  • Bateup H. S., Svenningsson P., Kuroiwa M., Gong S., Nishi A., Heintz N. and Greengard P. (2008) Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat. Neurosci. 11, 932939.
  • Beaulieu J. M., Sotnikova T. D., Yao W. D., Kockeritz L., Woodgett J. R., Gainetdinov R. R. and Caron M. G. (2004) Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc. Natl Acad. Sci. USA 101, 50995104.
  • Beaulieu J. M., Sotnikova T. D., Marion S., Lefkowitz R. J., Gainetdinov R. R. and Caron M. G. (2005) An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122, 261273.
  • Beaulieu J. M., Gainetdinov R. R. and Caron M. G. (2007a) The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol. Sci. 28, 166172.
  • Beaulieu J. M., Tirotta E., Sotnikova T. D., Masri B., Salahpour A., Gainetdinov R. R., Borrelli E. and Caron M. G. (2007b) Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J. Neurosci. 27, 881885.
  • Beaulieu J. M., Del'guidice T., Sotnikova T. D., Lemasson M. and Gainetdinov R. R. (2011) Beyond cAMP: the regulation of Akt and GSK3 by dopamine receptors. Front. Mol. Neurosci. 4, 38.
  • Bertran-Gonzalez J., Bosch C., Maroteaux M., Matamales M., Herve D., Valjent E. and Girault J. A. (2008) Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol. J. Neurosci. 28, 56715685.
  • Bertran-Gonzalez J., Herve D., Girault J. A. and Valjent E. (2010) What is the degree of segregation between striatonigral and striatopallidal projections? Front. Neuroanat., 4, 136.
  • Bhaskar P. T. and Hay N. (2007) The two TORCs and Akt. Dev. Cell 12, 487502.
  • Bibb J. A., Snyder G. L., Nishi A. et al. (1999) Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature 402, 669671.
  • Bouthenet M. L., Souil E., Martres M. P., Sokoloff P., Giros B. and Schwartz J. C. (1991) Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res. 564, 203219.
  • Brami-Cherrier K., Valjent E., Garcia M., Pages C., Hipskind R. A. and Caboche J. (2002) Dopamine induces a PI3-kinase-independent activation of Akt in striatal neurons: a new route to cAMP response element-binding protein phosphorylation. J. Neurosci. 22, 89118921.
  • Carriere A., Cargnello M., Julien L. A., Gao H., Bonneil E., Thibault P. and Roux P. P. (2008) Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr. Biol. 18, 12691277.
  • Chen P. C., Lao C. L. and Chen J. C. (2009) The D(3) dopamine receptor inhibits dopamine release in PC-12/hD3 cells by autoreceptor signaling via PP-2B, CK1, and Cdk-5. J. Neurochem. 110, 11801190.
  • Collins G. T., Newman A. H., Grundt P., Rice K. C., Husbands S. M., Chauvignac C., Chen J., Wang S. and Woods J. H. (2007) Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. Psychopharmacology 193, 159170.
  • Collo G., Bono F., Cavalleri L., Plebani L., Merlo Pich E., Millan M. J., Spano P. F. and Missale C. (2012) Pre-synaptic dopamine D(3) receptor mediates cocaine-induced structural plasticity in mesencephalic dopaminergic neurons via ERK and Akt pathways. J. Neurochem. 120, 765778.
  • Dunlop E. A., Dodd K. M., Seymour L. A. and Tee A. R. (2009) Mammalian target of rapamycin complex 1-mediated phosphorylation of eukaryotic initiation factor 4E-binding protein 1 requires multiple protein-protein interactions for substrate recognition. Cell. Signal. 21, 10731084.
  • Fasano C., Poirier A., DesGroseillers L. and Trudeau L. E. (2008) Chronic activation of the D2 dopamine autoreceptor inhibits synaptogenesis in mesencephalic dopaminergic neurons in vitro. Eur. J. Neurosci. 28, 14801490.
  • Foster K. G. and Fingar D. C. (2010) Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J. Biol. Chem. 285, 1407114077.
  • Gerfen C. R., Engber T. M., Mahan L. C., Susel Z., Chase T. N., Monsma F. J. Jr and Sibley D. R. (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250, 14291432.
  • Glickstein S. B., Desteno D. A., Hof P. R. and Schmauss C. (2005) Mice lacking dopamine D2 and D3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention. Cereb. Cortex 15, 10161024.
  • Gobert A., Billiras R., Cistarelli L. and Millan M. J. (2004) Quantification and pharmacological characterization of dialysate levels of noradrenaline in the striatum of freely-moving rats: release from adrenergic terminals and modulation by alpha2-autoreceptors. J. Neurosci. Methods 140, 141152.
  • Gong S., Zheng C., Doughty M. L. et al. (2003) A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 425, 917925.
  • Gyertyan I. and Saghy K. (2007) The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats. Eur. J. Pharmacol. 572, 171174.
  • Heidbreder C. A. and Newman A. H. (2010) Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders. Ann. N. Y. Acad. Sci. 1187, 434.
  • Hervé D. and Girault J. A. (2005) Signal transduction of dopamine receptors. In: Handbook of Chemical Neuroanatomy, 21; Dopamine, (Dunnett S. B., Bentivoglio M., Björklund A. and Hökfelt, T. eds), pp. 109151. Elsevier Science, Amsterdam.
  • Hoeffer C. A. and Klann E. (2010) mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci. 33, 6775.
  • Jaworski J. and Sheng M. (2006) The growing role of mTOR in neuronal development and plasticity. Mol. Neurobiol. 34, 205219.
  • Laszy J., Laszlovszky I. and Gyertyan I. (2005) Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology 179, 567575.
  • Le Moine C. and Bloch B. (1996) Expression of the D3 dopamine receptor in peptidergic neurons of the nucleus accumbens: comparison with the D1 and D2 dopamine receptors. Neuroscience 73, 131143.
  • Leroy K. and Brion J. P. (1999) Developmental expression and localization of glycogen synthase kinase-3beta in rat brain. J. Chem. Neuroanat. 16, 279293.
  • Mamane Y., Petroulakis E., LeBacquer O. and Sonenberg N. (2006) mTOR, translation initiation and cancer. Oncogene 25, 64166422.
  • Manning B. D. and Cantley L. C. (2007) AKT/PKB signaling: navigating downstream. Cell 129, 12611274.
  • Mannoury la Cour C., Salles M. J., Pasteau V. and Millan M. J. (2011) Signaling pathways leading to phosphorylation of Akt and GSK-3beta by activation of cloned human and rat cerebral Dand D receptors. Mol. Pharmacol. 79, 91105.
  • Matamales M., Bertran-Gonzalez J., Salomon L., Degos B., Deniau J. M., Valjent E., Herve D. and Girault J. A. (2009) Striatal medium-sized spiny neurons: identification by nuclear staining and study of neuronal subpopulations in BAC transgenic mice. PLoS ONE 4, e4770.
  • Millan M. J. and Brocco M. (2008) Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138. Therapie 63, 187229.
  • Millan M. J., Dekeyne A., Rivet J. M., Dubuffet T., Lavielle G. and Brocco M. (2000a) S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. J. Pharmacol. Exp. Ther. 293, 10631073.
  • Millan M. J., Gobert A., Newman-Tancredi A., Lejeune F., Cussac D., Rivet J. M., Audinot V., Dubuffet T. and Lavielle G. (2000b) S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J. Pharmacol. Exp. Ther. 293, 10481062.
  • Millan M. J., Buccafusco J. J., Loiseau F. et al. (2010) The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. Int. J. Neuropsychopharmacol. 13, 10351051.
  • Millan M. J., Agid Y., Brune M. et al. (2012) Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat. Rev. Drug Discov. 11, 141168.
  • Moore C. E., Xie J., Gomez E. and Herbert T. P. (2009) Identification of cAMP-dependent kinase as a third in vivo ribosomal protein S6 kinase in pancreatic beta-cells. J. Mol. Biol. 389, 480494.
  • Myskiw J. C., Rossato J. I., Bevilaqua L. R., Medina J. H., Izquierdo I. and Cammarota M. (2008) On the participation of mTOR in recognition memory. Neurobiol. Learn. Mem. 89, 338351.
  • Nair V. D. and Sealfon S. C. (2003) Agonist-specific transactivation of phosphoinositide 3-kinase signaling pathway mediated by the dopamine D2 receptor. J. Biol. Chem. 278, 4705347061.
  • Peineau S., Bradley C., Taghibiglou C., Doherty A., Bortolotto Z. A., Wang Y. T. and Collingridge G. L. (2008) The role of GSK-3 in synaptic plasticity. Br. J. Pharmacol. 153(Suppl 1), S428S437.
  • Pende M., Um S. H., Mieulet V. et al. (2004) S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol. Cell. Biol. 24, 31123124.
  • Peng S., Zhang Y., Zhang J., Wang H. and Ren B. (2010) ERK in learning and memory: a review of recent research. Int. J. Mol. Sci. 11, 222232.
  • Roux P. P., Shahbazian D., Vu H., Holz M. K., Cohen M. S., Taunton J., Sonenberg N. and Blenis J. (2007) RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J. Biol. Chem. 282, 1405614064.
  • Schwartz J. C., Diaz J., Bordet R., Griffon N., Perachon S., Pilon C., Ridray S. and Sokoloff P. (1998) Functional implications of multiple dopamine receptor subtypes: the D1/D3 receptor coexistence. Brain Res. Brain Res. Rev. 26, 236242.
  • Sokoloff P., Andrieux M., Besancon R., Pilon C., Martres M. P., Giros B. and Schwartz J. C. (1992) Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. Eur. J. Pharmacol. 225, 331337.
  • Sokoloff P., Diaz J., Le Foll B., Guillin O., Leriche L., Bezard E. and Gross C. (2006) The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol. Disord. Drug Targets 5, 2543.
  • Stoica L., Zhu P. J., Huang W., Zhou H., Kozma S. C. and Costa-Mattioli M. (2011) Selective pharmacogenetic inhibition of mammalian target of Rapamycin complex I (mTORC1) blocks long-term synaptic plasticity and memory storage. Proc. Natl Acad. Sci. USA 108, 37913796.
  • Surmeier D. J., Song W. J. and Yan Z. (1996) Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J. Neurosci. 16, 65796591.
  • Svenningsson P., Tzavara E. T., Carruthers R. et al. (2003) Diverse psychotomimetics act through a common signaling pathway. Science 302, 14121415.
  • Tang S. J., Reis G., Kang H., Gingras A. C., Sonenberg N. and Schuman E. M. (2002) A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc. Natl Acad. Sci. USA 99, 467472.
  • Thoreen C. C., Chantranupong L., Keys H. R., Wang T., Gray N. S. and Sabatini D. M. (2012) A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 485, 109113.
  • Valjent E., Bertran-Gonzalez J., Herve D., Fisone G. and Girault J. A. (2009) Looking BAC at striatal signaling: cell-specific analysis in new transgenic mice. Trends Neurosci. 32, 538547.
  • Valjent E., Bertran-Gonzalez J., Bowling H. et al. (2011) Haloperidol regulates the state of phosphorylation of ribosomal protein S6 via activation of PKA and phosphorylation of DARPP-32. Neuropsychopharmacology 36, 25612570.
  • Watson D. J., Loiseau F., Ingallinesi M., Millan M. J., Marsden C. A. and Fone K. C. (2012a) Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex. Neuropsychopharmacology 37, 770786.
  • Watson D. J., Marsden C. A., Millan M. J. and Fone K. C. (2012b) Blockade of dopamine D(3) but not D(2) receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment. Int. J. Neuropsychopharmacol. 15, 471484.
  • Wu J., McCallum S. E., Glick S. D. and Huang Y. (2011) Inhibition of the mammalian target of rapamycin pathway by rapamycin blocks cocaine-induced locomotor sensitization. Neuroscience 172, 104109.
  • Zar J. L. (1999) Biostatistical Analysis. Prentice-Hall Inc., Upper Saddle River, NJ.